Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparison of live and fixed cell-based assay performance: implications for the diagnosis of MOGAD in a low-middle income country.

Frontiers in immunology - 1 Jan 2023

Pandit Lekha, D'Cunha Anitha, Malli Chaithra, Sudhir Akshatha

Abstract excerpt

Background: Though considered optimal, live cell-based assay (LCBA) is often unavailable for the diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disorders (MOGAD) in resource-poor regions. This study was undertaken to determine the agreement between LCBA and the widely available fixed cell-based assay (FCBA), for recommending testing guidelines within our region. Method: All consecutive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biological Assay
Share to Developing Countries

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Germany

Share to Phenotype

Share to Registries

Source

Open in PubMed Open full text

Identifiers

PMID: 37705970
DOI: 10.3389/fimmu.2023.1252650
PMCID: PMC10495565

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparison of live and fixed cell-based assay performance: implications for the diagnosis of MOGAD in a low-middle income country.PMID 37705970Read ↗

Ongoing Challenges in the Diagnosis of Myelin Oligodendrocyte Glycoprotein Antibody–Associated DiseaseSemantic proximity Read ↗

Assessment of international MOGAD diagnostic criteria in patients with overlapping MOG-associated disease and multiple sclerosis phenotypes.Semantic proximity Read ↗

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): Pathophysiology, Clinical Patterns, and Therapeutic Challenges of Intractable and Severe FormsSemantic proximity Read ↗

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Insights into pathogenesis and biomarkers of prognosisSemantic proximity Read ↗

[Clinical features and modern diagnostic criteria of the disease associated with myelin oligodendrocyte glycoprotein antibody disease].Semantic proximity Read ↗

MOGAD update: new phenotypes in the expanding clinical spectrum.Semantic proximity Read ↗

Frequency of myelin oligodendrocyte glycoprotein antibodies in a large cohort of neurological patientsSemantic proximity Read ↗

Myelin Oligodendrocyte Glycoprotein: Deciphering a Target in Inflammatory Demyelinating DiseasesSemantic proximity Read ↗

Unmet Needs in the Care of Patients with Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Antibody Associated Disease: Insights from GermanySemantic proximity Read ↗

Anti-MOG antibody: The history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination.Semantic proximity Read ↗

E.U. paediatric MOG consortium consensus: Part 1 - Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders.Semantic proximity Read ↗

Characteristics of aseptic meningitis-like attack-an underestimated phenotype of myelin oligodendrocyte glycoprotein antibody-associated disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.